Cosmetic surgery may help patients quit smoking

"Our results show an association between cosmetic surgery and smoking cessation at long-term follow-up," comments lead author Aaron C. Van Slyke, MD, MSc, of University of British Columbia, Vancouver. "Surgeons who request preoperative smoking cessation may influence patients' long-term smoking status."
Many Cosmetic Surgery Patients Quit or Reduce Smoking
The follow-up study included 85 patients who were smokers when evaluated for cosmetic surgery. Like most plastic surgeons, Dr. Van Slyke and colleagues required patients to refrain from smoking for at least two weeks before elective procedures. Those instructions reflect a well-demonstrated increase in wound healing problems and other negative outcomes among smokers after plastic surgery.
Five years after cosmetic surgery, 47 patients responded to a follow-up survey. Most of the patients were women; the average age was 40 years. The most common procedures were "tummy tuck" (abdominoplasty), breast lift (mastopexy), and facelift. After exclusion of five "social" smokers, the study included 42 patients who were daily smokers before cosmetic surgery.
In the follow-up survey, about 40 percent of patients said they no longer smoked cigarettes on a daily basis. Nearly one-fourth had not smoked at all since their cosmetic surgery procedure.
Most patients said they had reduced their cigarette use by any amount. Seventy percent agreed that discussing their increased surgical risks with the plastic surgeon influenced their ability to quit or reduce smoking.
However, one-half of patients admitted they did not follow the instructions to refrain from cigarette use before surgery. Nearly one-fourth continued to smoke up to the day of their procedure. Dr. Van Slyke and colleagues did not test to confirm whether patients had stopped smoking.
The complication rate after cosmetic surgery was higher in patients who continued to smoke: 24 percent versus 14 percent. (The difference was not statistically significant.) More serious wound-healing complications occurred in two patients -- both of whom did not follow the instructions to stop smoking.
Due to the negative effects of smoking on wound healing, many plastic surgeons are unwilling to perform cosmetic surgery procedures in patients who smoke. Compared to studies in other groups, the new findings suggest that cosmetic surgery patients seem more likely to quit or cut back on smoking at long-term follow-up. "This is consistent with previous research showing patients who seek to obtain cosmetic surgery are more motivated to sustain positive lifestyle changes," Dr. Van Slyke and coauthors write.
The results suggest that patients were more motivated to quit by "targeted messaging" with specific examples of the negative effects of smoking, rather than by a description of the general health benefits of smoking cessation. The authors conclude, "[T]he dialogue between plastic surgeon and patient during the cosmetic surgery consultation serves as a unique moment to provide targeted smoking cessation counseling that may persist well beyond the surgical interaction."


for more information visit our product website:Buy Femalegra 100mg Pills Online 



Location: United States

Comments

Post a Comment

Popular posts from this blog

Younger mothers are more likely to engage in risky drinking during and after pregnancy

Researchers recruited 456 pregnant women, ages 13 to 42 years, at an urban prenatal clinic. The women (64% African-American, 36% White) were interviewed about alcohol use during pregnancy, at delivery, and again at six, 10, 14, and 16 years postpartum. The majority of mothers (66%) were identified as having low-risk trajectories of alcohol use during the 17-year span. However, maternal age at first birth predicted one high-risk group: younger mothers were more likely to engage in risky drinking early in pregnancy, which continued for six to 14 years postpartum. The authors suggest that these results can help physicians target mothers who are likely to exceed national guidelines calling for abstinence during pregnancy, and no more than seven drinks per week during postpartum. for more information visit our product website: Buy Caverta 100 mg Online 
Read more

Serotonin is a neurotransmitter which helps brain cells communicate with one another, playing important roles in stabilising mood and regulating stress. Despite its importance, current models to explain serotonin's function in the brain remain incomplete. Now, in a review paper published this month in the Journal of Psychopharmacology, researchers from Imperial College London suggest that serotonin pathways are more nuanced than previously thought. They argue that the existing view should be updated to incorporate a 'two-pronged' model of how serotonin acts. The researchers believe their updated model could have implications for treating recalcitrant mental health conditions, including depression, obsessive compulsive disorder and addiction, and could exploit the therapeutic potential of psychedelic drugs. In the brain, serotonin acts via a number of sites called 'receptors' and serotonin has at least 14 of these. Brain drugs such antidepressants, antipsychotics and psychedelics are known to interact with serotonin receptors and two of these are thought to be particularly important -- the so-called serotonin 1A and 2A receptors. For patients with depression, commonly prescribed drugs called SSRIs (Selective Serotonin Reuptake Inhibitors) can help to relieve symptoms by boosting levels of serotonin in the brain. Evidence suggests an important part of how they work is to increase activity at the serotonin 1A receptor, which reduces brain activity in important stress circuitry, thereby helping a person cope better. In contrast, psychedelic compounds such as LSD and psilocybin (the psychoactive component of magic mushrooms), are thought to act primarily on the serotonin 2A receptor. Accumulating evidence suggests that psychedelics with psychotherapy can be an effective treatment for certain mental illnesses and, with a focus on the 2A receptor, the authors' paper attempts to explain why. Writing in the review paper, the researchers say that while the traditional view of developing psychiatric treatments has been focused on promoting 1A activity and often blocking the 2A, the therapeutic importance of activating the 2A pathway -- the mechanism by which psychedelics have their effect -- has been largely overlooked. "We may have got it wrong in the past," said Dr Robin Carhart-Harris, Head of Psychedelic Research at Imperial and lead author on the paper. "Activating serotonin 2A receptors may be a good thing, as it makes individuals very sensitive to context and to their environment. Crucially, if that is made therapeutic, then the combination can be very effective. This is how psychedelics work -- they make people sensitive to context and 'open' to change via activating the 2A receptor." According to the researchers, the 1A and 2A pathways form part of a two-pronged approach which may have evolved to help us adapt to adversity. By triggering the 1A pathway, serotonin can make situations less stressful, helping us to become more resilient. However, they argue that this approach may not always be enough, and that in extreme crises, the 2A pathway may kick in to rapidly open a window of plasticity in which fundamental changes in outlook and behaviour can occur. Growing evidence shows that in conditions such as treatment-resistant depression, obsessive compulsive disorder and addiction, certain brain circuitry may become 'stamped in' and resistant to change. The researchers suggest that in such cases, activating the 2A pathway -- such as through psychedelics -- could potentially offer a way to break the cycle, helping patients to change negative behaviours and thought patterns which have become entrenched. By enabling the brain to enter into a more adaptive or 'plastic' state and providing patients with a suitably enriched clinical environment when they receive a drug treatment, clinicians could create a window for therapy, effectively making patients more receptive to psychotherapy. According to the authors, their updated model of how serotonin acts in the brain could lead to a shift in psychiatric care, with the potential to move patients from enduring a condition using current pharmacological treatments, to actively addressing their condition by fundamentally modifying behaviours and thinking. Professor David Nutt, Director of Neuropsychopharmacology in Imperial's Division of Brain Sciences, explained: "This is an exciting and novel insight into the role of serotonin and its receptors in recovery from depression that I hope may inspire more research into develop 5-HT2A receptor drugs as new treatments." Dr Carhart-Harris added: "I think our model suggests that you cannot just administer a drug in isolation, at least certainly not psychedelics, and the same may also true for SSRIs. We need to pay more attention to the context in which medications are given. We have to acknowledge the evidence which shows that environment is a critical component of how our biology is expressed." He added: "In psychiatry, as in science, things are rarely black and white, and part of the approach we're promoting is to have a more sophisticated model of mental healthcare that isn't just a drug or psychotherapy, it's both. I believe this is the future." 'Serotonin and brain function: a tale of two receptors' by Robin Carhart-Harris and David Nutt is published in the Journal of Psychopharmacology.

A Finnish research group worked with 11 young men and 16 young women who had a heavy 10-year alcohol use, and compared them with 12 young men and 13 young women who had little or no alcohol use. All were between 23 to 28 years old at the time the measurements were taken. The researchers examined the responses of the brain to being stimulated by magnetic pulses -- known as Transcranial Magnetic Stimulation (TMS), which activates brain neurons. The brain activity was measured using EEG (electroencephalogram). Previously, the researchers had found that heavy alcohol users showed a greater electrical response in the cortex of the brain than non-alcohol users, which indicates that there had been long-term changes to how the brain responds. This time, they found that young men and young women responded differently, with males showing a greater increase in electrical activity in the brain in response to a TMS pulse. As researcher Dr Outi Kaarre (University of Eastern Finland and Kuopio ...
Read more

Given the choice, zebrafish willingly dose themselves with opioids

Image
Zebrafish at College of Utah Well being Centralized Zebrafish Animal Useful resource (CZAR) facility. Credit score: College of Utah Well being Because the opioid disaster escalates, the science behind dependancy stays poorly understood. To handle this want, researchers at College of Utah Well being devised a system that allowed zebrafish, a small tropical fish, to self-administer doses of hydrocodone, an opioid generally prescribed to folks for ache. After one-week, the fish had elevated their drug-seeking habits, even when doing so required them to place themselves in dangerous circumstances. Additional, 48-hours after the final publicity, conditioned fish confirmed indicators of hysteria, a trademark of withdrawal. Printed August 25 on-line within the journal  Behavioral Mind Analysis , this research affords a brand new method to discover the organic pathways behind dependancy and withdrawal that might result in new therapies to deal with depen...
Read more